Novartis AG Chief Touts “Industry-Best” Biosimilars

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Novartis CEO Joe Jimenez has outlined the firm’s determination to be the major force in biosimilars. Speaking as the Swiss major posted its financials for the second quarter (see link), Mr Jimenez (pictured) highlighted the advancement of its biosimilars pipeline. He noted that Novartis’ Sandoz unit is running seven Phase III studies across five biosimilar molecules, “more than any other company has in our industry”.

Help employers find you! Check out all the jobs and post your resume.